HIV reverse transcriptase

Assets acting on this target.

Class
Non-nucleoside reverse transcriptase inhibitor (NNRTI)

HIV reverse transcriptase is a viral enzyme that copies the virus's single-stranded RNA genome into double-stranded DNA, a step required before the genetic material can integrate into a host cell's chromosome and establish infection. Because human cells have no equivalent enzyme, reverse transcriptase is an attractive and selective drug target. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are a chemically diverse class of small molecules that bind a pocket on the enzyme distinct from the site where the natural building blocks of DNA are incorporated. This binding distorts the enzyme's shape and blocks its catalytic motion, halting DNA synthesis without needing to mimic a natural nucleotide. NNRTIs are used alongside nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), which block the same enzyme through a different, competitive mechanism, and often with a third class targeting a separate step of the viral life cycle. Combining agents that inhibit the same enzyme through different mechanisms, or that hit different life-cycle stages, raises the number of independent mutations the virus must accumulate to escape treatment, which is the biological rationale behind combination antiretroviral therapy. This mechanism is central to chronic suppression of HIV infection and to reducing transmission risk.

By indication

Related mechanisms

HIV reverse transcriptase drugs compared

14 drugs, stage by indication
14 drugs acting on HIV reverse transcriptase: developer, modality, furthest stage and stage in each indication. Furthest stage first.
DrugDeveloperModalityFurthest stageStage by indication
Cabotegravir/rilpivirine (Cabenuva)Cabenuva / VocabriaViiV Healthcaresmall moleculeApprovedApproved in HIV
DoravirinePifeltroMerck & Co.small moleculeApprovedApproved in HIV
Doravirine/islatravir (Idvynso)IdvynsoMerck & Co.small moleculeApprovedApproved in HIV
Emtricitabine (Emtriva)EmtrivaGilead Sciencessmall moleculeApprovedApproved in HIV
Emtricitabine/tenofovir disoproxil fumarateTruvadaGilead Sciencessmall molecule combinationApprovedApproved in HIV
EtravirineIntelenceJohnson & Johnsonsmall moleculeApprovedApproved in HIV
RilpivirineEdurantJohnson & Johnsonsmall moleculeApprovedApproved in HIV
Tenofovir alafenamide/emtricitabineDescovyGilead Sciencessmall molecule combinationApprovedApproved in HIV
AzvudineFNCHenan Genuine Biotechsmall moleculePhase 3Phase 3 in COVID-19; Phase 3 in HIV
DapivirineDapivirine Vaginal RingPopulation Councilsmall moleculePhase 3Phase 3 in HIV
ElsulfavirineElpidaRoche, Viriomsmall moleculePhase 2/3Phase 2/3 in HIV
UlonivirineMerck & Co.small moleculePhase 2/3Phase 2/3 in HIV
CL-197Henan Genuine Biotechsmall moleculePhase 2Phase 2 in HIV
AinuovirineJiangsu Aidea Pharmaceutical Group, Kainos Medicinesmall moleculePhase 1Phase 1 in HIV

← all mechanisms